Replies to post #185927 on Biotech Values

[frontiers]

ACHN clearly tried to hide this news amid the cornucopia of news flow from JPM. Sleazy.

Hide??? Of course not, there's an SEC filing for all to see!!

Sleazy??? The market did NOT agree with you at all!!!!!
ACHN stock did not take a hit, in fact it's up a little.

BTW, there's a new preso posted at the ACHN website that provides info on the new trials planned --

– 1Q15: ACH-3102+sovaldi Phase 2 “Proxy” Study, SVR12 from 6-week treatment cohort

– 1Q15: ACH-3422 Phase 1 monotherapy for GT 2/3

– 1H15: ACH-3102 Phase 1 monotherapy for GT2/3

– 1H15: Initiation of ACH-3422+ACH-3102 Phase 2 program (SPARTA DOUBLET)

– 1H15: Initiation of ACH-3102+sovaprevir+sovaldi 4 week study

– 2H15: Initiation of ACH-3102+sovaprevir+ACH-3422 Phase 2 program
(SPARTA TRIPLET)